Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Stuart Smith

Internal Medicine Warrensburg, MO Doctor of Osteopathy

NPI 1659375525 CMS profile 30023

511 Burkarth Rd, Warrensburg, MO 64093

Open in the dashboard

General payments

$2,422

172 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Stuart Smith of Warrensburg, MO is reported in the CMS Open Payments database as having received $2,422 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $228 16
2021 General $976 65
2020 General $525 39
2019 General $693 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Smith
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stuart Smith were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stuart Smith Internal Medicine median Middle half National median
2019 $693 $159 $48–$570 $163
2020 $525 $119 $33–$402 $114
2021 $976 $135 $37–$521 $132
2022 $228 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Pfizer Inc. $344 30 payments
  2. AstraZeneca Pharmaceuticals LP $246 15 payments
  3. Janssen Pharmaceuticals, Inc $240 17 payments
  4. Lilly USA, LLC $182 13 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $176 11 payments
  6. Novo Nordisk Inc $163 12 payments
  7. Merck Sharp & Dohme Corporation $152 11 payments
  8. Amgen Inc. $103 7 payments
  9. AbbVie, Inc. $103 7 payments
  10. Amarin Pharma Inc. $87 6 payments
  11. Other $627 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,422 172 payments
Products named General payments · program years 2019–2022
  1. XARELTO $240 17 payments
  2. COLOGUARD $160 13 payments
  3. TRULICITY $142 10 payments
  4. BELSOMRA $140 10 payments
  5. JANUVIA $137 10 payments
  6. Ozempic $134 10 payments
  7. ELIQUIS $123 13 payments
  8. EUCRISA $122 10 payments
  9. RYBELSUS $121 9 payments
  10. CHANTIX $118 10 payments
  11. Other $2,542 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$3,878

Medicare's payments for the services billed

Medicare patients

503

Average age 75

Services billed

731

281 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 37%
Ischemic heart disease 35%
Depression 34%
Chronic kidney disease 31%
Atrial fibrillation 27%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record